Tag: Shreekanth Katti
Overstepping the mark
The requirement to submit a test licence in the drugs and cosmetics rules goes beyond the ambit of the Parent Act, and is a hindrance to R&D for pharma companies, writes Syngene International's Shreekanth Katti
LATEST ON VANTAGE ASIA
Knowing is half the battle
Sadaff Habib, an independent arbitrator based in Dubai, points out the major challenges in local arbitration and offers key tips for Chinese businesses
